NASDAQ : PLSE
Pulse Biosciences, Inc. — Key statistics
Healthcare · Medical Instruments & Supplies · United States
Last price 55.48 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.96B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.73B |
| Enterprise Value | 3.63B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 71.32M |
| Shares Outstanding | 71.32M |
| Shares Change (YoY) | +7.37% |
| Shares Change (QoQ) | +1.77% |
| Owned by Insiders (%) | 70.16% |
| Owned by Institutions (%) | 15.21% |
| Float | 20.65M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3,144.21 |
| Forward PS | 1,261.59 |
| PB Ratio | 37.17 |
| P/TBV Ratio | 38.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3,064.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.63 |
| Quick Ratio | 9.27 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -78.49% |
| Return on Assets (ROA) | -44.34% |
| Return on Invested Capital (ROIC) | -47.74% |
| Return on Capital Employed (ROCE) | -79.97% |
| Weighted Average Cost of Capital (WACC) | 12.86% |
| Revenue Per Employee | $10,216 |
| Profits Per Employee | -$690,138 |
| Employee Count | 116 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 8.24 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.57 |
| 52-Week Price Change | +205.32% |
| 50-Day Moving Average | 51.08 |
| 200-Day Moving Average | 31.35 |
| Relative Strength Index (RSI) | 53.10 |
| Average Volume (20 Days) | 382,710 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.00M |
| Short Previous Month | 3.31M |
| Short % of Shares Out | 4.21% |
| Short % of Float | 14.55% |
| Short Ratio (days to cover) | 5.88 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.19M |
| Gross Profit | 3,000 |
| Operating Income | -83.64M |
| Pretax Income | -80.06M |
| Net Income | -80.06M |
| EBITDA | -82.62M |
| EBIT | -83.64M |
| Loss Per Share | -$1.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 101.62M |
| Total Debt | 6.77M |
| Net Cash | 94.85M |
| Net Cash Per Share | $1.33 |
| Equity (Book Value) | 99.50M |
| Book Value Per Share | 1.41 |
| Working Capital | 94.72M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -61.10M |
| Capital Expenditures | -290,000 |
| Depreciation & Amortization | 1.02M |
| Net Borrowing | n/a |
| Free Cash Flow | -61.39M |
| FCF Per Share | -$0.86 |
Margins
| Measure | Value |
|---|
| Gross Margin | 0.25% |
| Operating Margin | -7,058.40% |
| Pretax Margin | -6,755.78% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.37% |
| Shareholder Yield | -7.37% |
| Earnings Yield | -2.25% |
| FCF Yield | -1.65% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $62.33 |
| Price Target Difference | 19.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 263.60% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 38.97 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |